Advertisement

Pharmaceutisch Weekblad

, Volume 9, Issue 2, pp 98–103 | Cite as

Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients

  • Roelof Van Dalen
  • Tom B. Vree
  • Ita M. Baars
Pharmacokinetics and Organ Dysfunction

Abstract

A pharmacokinetic study after a single dose of ceftriaxone, cefoxitin, cefuroxime and ceftazidime was performed to investigate the influence of protein binding and severity of disease on the renal elimination. In intensive-care patients drug-protein binding was substantially less compared to that in volunteers and patients with less complicated diseases. This did not result in increased elimination but, due to increased apparent volumes of distribution, prolonged half-life times were observed. Consequently, in patients with complicated disease states a dosage regimen should be based on pharmacokinetic studies performed in a similar patient group.

Key words

Cefoxitin Ceftazidime Ceftriaxone Cefuroxime Chromatography, high pressure liquid Kidney diseases Pharmacokinetics Protein binding 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tillement JP, Lhoste F, Giudicelli JF. Diseases and drug protein binding. Clin Pharmacokinet 1978;3:144–54.Google Scholar
  2. 2.
    Lindup WE, L'eorme MC. Plasma protein binding of drugs. Br Med J 1981;282:212–4.Google Scholar
  3. 3.
    Svensson CK, Woodruff MN, Baxter JG, Lalka D. Free drug concentration monitoring in clinical practice. Rationale and current status. Clin Pharmacokinet 1986;11:450–69.Google Scholar
  4. 4.
    Rowland M. Protein binding and drug clearance. Clin Pharmacokinet 1984;9(suppl 1):10–7.Google Scholar
  5. 5.
    Wise R. The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin Pharmacokinet 1986;11:470–82.Google Scholar
  6. 6.
    Stoeckel K, McNamara PJ, Brandt R, Plozza-Nottebrock H, Ziegler WH. Effects of concentrationdependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther 1981;29:650–7.Google Scholar
  7. 7.
    Brogden RN, Heel RC, Speight TM, Avery GS. Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 1979; 17:1–37.Google Scholar
  8. 8.
    Foord RD. Cefuroxime: Human pharmacokinetics. Antimicrob Agents Chemother 1976;9:741–7.Google Scholar
  9. 9.
    Harding SM, Monro AJ, Thornton JE, Ayrton J, Hogg MIJ. The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. J Antimicrob Chemother 1981;8(suppl B):263–72.Google Scholar
  10. 10.
    Metzler CM, Elfring GL, McEwen AJ. A package of computer programs for pharmacokinetic modeling. Biometrics 1974;30:562–3.Google Scholar
  11. 11.
    Greenblatt DJ, Koch-Weser J. Clinical pharmacokinetics. 1. N Engl J Med 1975;293:702–5.Google Scholar
  12. 12.
    Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ. Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults. Antimicrob Agents Chemother 1982;22:816–23.Google Scholar
  13. 13.
    Patel IH, Kaplan SA. Pharmacokinetic profile of ceftriaxone in man. Am J Med 1984;77(suppl4C):17–25.Google Scholar
  14. 14.
    Scully BE, Fu KP, Neu HC. Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection. Am J Med 1984;77(suppl4C):112–6.Google Scholar
  15. 15.
    Joos B, Luethy R, Muehlen E, Siegenthaler W. Variability of ceftriaxone pharmacokinetics in hospitalized patients with severe infections. Am J Med 1984;77(suppl4C):59–62.Google Scholar
  16. 16.
    Patel IH, Sugihara JG, Wėinfeld RE, Wong EGC, Siemsen AW, Berman SJ. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother 1984;25:438–42.Google Scholar
  17. 17.
    Ti T-Y, Fortin L, Kreeft JH, East DS, Ogilvie RJ, Somerville PJ. Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis. Antimicrob Agents Chemother 1984;25:83–7.Google Scholar
  18. 18.
    Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E. Single-dose ceftriaxone kinetics in functionally anephric patients. Clin Pharmacol Ther 1983;33:633–41.Google Scholar
  19. 19.
    Cohen D, Appel GB, Scully B, Neu HC. Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis. Antimicrob Agents Chemother 1983;24:529–32.Google Scholar
  20. 20.
    Van Dalen R, Vree TB, Baars AM, Termond ESF. Dosage adjustment for ceftazidime in patients with impaired renal function. Eur J Clin Pharmacol 1986;30:597–605.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1987

Authors and Affiliations

  • Roelof Van Dalen
    • 1
  • Tom B. Vree
    • 2
  • Ita M. Baars
    • 2
  1. 1.Department of Intensive CareSt. Radboud HospitalHB NijmegenThe Netherlands
  2. 2.Department of Clinical PharmacySt. Radboud HospitalHB NijmegenThe Netherlands

Personalised recommendations